New money for Nova to advance protein therapy for rare skin disorder

29 April 2025

Early-stage biotech Nova Anchora has secured a new investment to move its lead therapy for epidermolysis bullosa (EB) closer to clinical trials.

The funds will support continued preclinical development of NvA-011, a topical protein therapy for dystrophic EB (DEB), the most severe form of the disease. The therapy is designed to restore the function of type VII collagen, a protein that is deficient in people with DEB.

Founded in 2021 and based in San Francisco, Nova is developing its therapy using technology licensed from Stanford University. NvA-011 received orphan drug designation from the US Food and Drug Administration in 2024.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK